Todd Brady Acquires 250,000 Shares of Aldeyra Therapeutics (NASDAQ:ALDX) Stock

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) CEO Todd Brady acquired 250,000 shares of Aldeyra Therapeutics stock in a transaction dated Wednesday, June 3rd. The stock was acquired at an average cost of $1.67 per share, with a total value of $417,500.00. Following the completion of the transaction, the chief executive officer directly owned 1,721,298 shares of the company’s stock, valued at $2,874,567.66. This trade represents a 16.99% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Aldeyra Therapeutics Trading Down 7.4%

ALDX opened at $1.63 on Friday. Aldeyra Therapeutics, Inc. has a 1-year low of $1.07 and a 1-year high of $6.18. The stock has a market capitalization of $98.32 million, a price-to-earnings ratio of -3.54 and a beta of 1.19. The business has a 50 day moving average of $1.68 and a 200-day moving average of $3.68.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.07. Equities analysts predict that Aldeyra Therapeutics, Inc. will post -0.43 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on ALDX. Weiss Ratings lowered Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 20th. Wall Street Zen upgraded Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright reiterated a “neutral” rating and set a $2.00 price objective (down from $10.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, March 18th. Finally, BTIG Research reiterated a “buy” rating on shares of Aldeyra Therapeutics in a research note on Tuesday, March 17th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.50.

Institutional Trading of Aldeyra Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ALDX. Abel Hall LLC acquired a new stake in shares of Aldeyra Therapeutics in the first quarter valued at $26,000. Krilogy Financial LLC bought a new position in Aldeyra Therapeutics in the first quarter valued at about $26,000. Chicago Partners Investment Group LLC bought a new position in Aldeyra Therapeutics in the first quarter valued at about $33,000. Caption Management LLC boosted its holdings in Aldeyra Therapeutics by 110.6% in the second quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 132,358 shares during the last quarter. Finally, Inspirion Wealth Advisors LLC bought a new position in Aldeyra Therapeutics in the fourth quarter valued at about $52,000. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.